EU MDR 2017/745 compliance is not a checklist. It is a clinical evidence architecture that must be designed from protocol version 1. These six strategies — drawn from the operational experience of former Notified Body reviewers at Eclevar MedTech — cover every major compliance lever available to device manufacturers navigating the current regulatory landscape.
The Clinical Evaluation Report is the single most scrutinised document in a medical device technical file. Under EU MDR 2017/745, a CER that was sufficient under MDD is rarely sufficient today. Notified Bodies now require a validated Clinical Evaluation Plan (CEP) before the evaluation begins, a PRISMA-compliant systematic literature review, and a benefit-risk conclusion explicitly benchmarked against the state of the art for the indication.
The most common CER failure mode is not insufficient data — it is insufficient methodology documentation. A CEP produced after the CER, a literature section that is a citation list rather than a systematic review, or a benefit-risk conclusion that does not reference alternative treatments are the three most frequent causes of major non-conformity findings at technical file review.
Post-Market Clinical Follow-Up is not a post-market activity — it is a compliance architecture that must be designed in parallel with the CE marking strategy. Manufacturers who treat PMCF as an afterthought consistently discover that their post-market data collection is either insufficient for Notified Body review, or incompatible with the data gaps identified in their CER.
The PMCF Plan must specify which PMCF activities will be conducted (surveys, clinical investigations, registry participation, literature monitoring), at what frequency, and how each activity addresses a specific unresolved data gap from the CER. A PMCF Plan that lists activities without gap-mapping is a common and consequential finding.
Your choice of EDC platform directly determines your compliance posture. Most EDC systems on the market were built for pharmaceutical trials and require significant configuration to meet EU MDR requirements. Configuration is not compliance — it is risk. A platform that requires manual Annex XIV field mapping, third-party audit trail modules, or post-hoc CDISC transformation is a compliance liability disguised as a software contract.
Powered by MILO Health — EU MDR-native EDC
For Class IIb and III implantable devices — particularly in orthopedics, cardiovascular, and neuromodulation — national registries are increasingly the primary data source for long-term PMCF. Notified Bodies are now explicitly asking manufacturers how their PMCF programs connect to the NJR (UK), EPRD (Germany), Swespine (Sweden/Denmark), and EUDAMED (EU-wide). Manufacturers without a registry strategy are relying entirely on manufacturer-controlled surveys — a position that is becoming increasingly difficult to defend at renewal.
Registry participation requires early institutional engagement — not a post-market addition. Site agreements, data access protocols, and UDI linkage must be established before first patient enrolment. The EDC platform must be capable of ingesting registry data feeds and reconciling them with eCRF data in a single study environment.
The most expensive data management strategy is reactive data management. Manufacturers who approach audit readiness as a pre-submission activity — rather than as a structural property of the study design — consistently face critical TMF findings, delayed database lock, and costly data remediation. Under EU MDR, the audit trail is not a post-hoc report: it is a real-time compliance record that begins at first patient in.
A structurally audit-ready data management program means: the Data Management Plan (DMP) is approved before eCRF build; the Data Validation Plan (DVP) is pre-specified; all edit checks are documented and version-controlled; query resolution workflows are traceable; and database lock follows a documented, multi-party sign-off procedure.
The most fundamental shift introduced by EU MDR relative to MDD is the requirement for continuous clinical evaluation. CE marking is not a destination — it is a maintenance obligation. Manufacturers who secured CE marking and then treated post-market compliance as a periodic reporting exercise are now discovering that their surveillance audits surface critical findings that were accumulating silently over years.
Under Articles 83–86 of EU MDR, manufacturers must maintain a Post-Market Surveillance system that continuously feeds into the Post-Market Surveillance Report (PMSR) or Periodic Safety Update Report (PSUR), which in turn drives the annual CER update, which in turn informs the PMCF Plan revision. This is a closed loop — not a series of independent document updates.
Most CROs can execute compliance activities. Very few can design them from a Notified Body perspective — before the first protocol is written. Eclevar's compliance programs are structured around three institutional advantages that are not available elsewhere.
Our team of former Notified Body reviewers will assess your current EU MDR compliance posture across CER, PMCF, data management, and EDC — and identify the highest-risk gaps before your next Notified Body interaction.
Each strategy above has a corresponding regulatory document and an Eclevar service page. Use this table as your compliance navigation index.
| Compliance area | Key regulatory document | Priority for Class III | Eclevar service |
|---|---|---|---|
| Clinical Evaluation Report (CER) | EU MDR Art. 61 Annex XIV Part A MDCG 2020-13 | Mandatory | CER services |
| PMCF Program | Annex XIV Part B MDCG 2020-7 | Mandatory | PMCF services |
| EDC / eCRF Platform | ISO 14155:2020 21 CFR Part 11 | Mandatory | MILO Health EDC |
| Registry Integration | Annex XIV Part B EUDAMED | Recommended | RWE & registry |
| Data Management | ISO 14155:2020 Cl. 8 CDISC CDASH | Mandatory | Data management |
| Post-Market Surveillance | EU MDR Art. 83–86 PSUR / PMSR | Ongoing | PMCF activities |
| SSCP (Class III, implantables) | EU MDR Art. 32 MDCG 2019-9 Rev.1 | Mandatory | Medical writing |
